HC Wainwright Reiterates “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $310.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 11.75% from the company’s current price.

Several other brokerages have also recently issued reports on KRYS. Guggenheim boosted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Jefferies Financial Group boosted their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. The Goldman Sachs Group boosted their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Bank of America boosted their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Trading Up 4.3%

KRYS stock traded up $11.37 on Monday, hitting $277.41. The company’s stock had a trading volume of 319,788 shares, compared to its average volume of 287,952. The firm has a 50 day moving average of $261.72 and a two-hundred day moving average of $246.50. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $298.30. The stock has a market cap of $8.17 billion, a price-to-earnings ratio of 40.48 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. As a group, equities analysts forecast that Krystal Biotech will post 7.58 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Daniel Janney sold 11,803 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares in the company, valued at approximately $20,198,817.87. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the transaction, the insider owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This trade represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 in the last quarter. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the period. Optimize Financial Inc lifted its holdings in shares of Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after acquiring an additional 40 shares during the period. Perigon Wealth Management LLC lifted its holdings in shares of Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after acquiring an additional 41 shares during the period. Regal Investment Advisors LLC lifted its holdings in shares of Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after acquiring an additional 44 shares during the period. Finally, Torray Investment Partners LLC lifted its holdings in shares of Krystal Biotech by 0.4% during the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after acquiring an additional 47 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.